Open Orphan PLC New contract win with Oxford BioTherapeutics (5449R)
March 09 2021 - 2:00AM
UK Regulatory
TIDMORPH
RNS Number : 5449R
Open Orphan PLC
09 March 2021
9 March 2021
Open Orphan plc
("Open Orphan" or the "Company")
New contract win with Oxford BioTherapeutics
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
pharmaceutical services CRO and a world leader in vaccine and
antiviral testing using human challenge clinical trials, announces
its subsidiary Venn Life Sciences ("Venn") has been awarded a
contract for a study with Oxford BioTherapeutics, a clinical stage
oncology company with a pipeline of immune-oncology and
antibody-drug conjugate-based therapies.
This is a phase I, open-label, dose finding study which will be
used to assess the safety, tolerability, pharmacokinetics and
preliminary efficacy of OBT076, a CD205-directed antibody-drug
conjugate, in recurrent and/or metastatic CD205-positive solid
tumours and in women with CD205-positive HER2-negative metastatic
breast cancer.
For this study, the Venn Paris team will deliver high-quality
data management and statistics services. Venn's team in Paris are
highly regarded in the field as one of the leading providers in
this area which is a perfect complement to the Company's London
offering. The study is due to start immediately.
Cathal Friel, Executive Chairman, Open Orphan, commented: "We
are delighted to be in a position to announce another contract win
for the Paris team. This deal further demonstrates Open Orphan's
ability to execute on its significant pipeline of contracts with
important pharmaceutical businesses.
"Oxford BioTherapeutics is a clinical stage oncology company
with a pipeline of first-in-class therapies aiming to fulfil major
unmet patient needs by targeting difficult-to-treat cancers. The
Venn team are looking forward to assisting with the study and
providing the preliminary data required to advance this breast
cancer trial."
Dr Rahim Fandi, MD, PhD Oxford BioTherapeutics CMO commented:
"We are delighted to work with Venn and are sure that Oxford
BioTherapeutics will benefit from their expertise."
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & +44 (0)20 7933 8780 or openorphan@walbrookpr.com
IR)
+44 (0)7876 741 001 / +44
Anna Dunphy / Paul McManus (0)7980 541 893
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
pharmaceutical service/contract research company that is a world
leader in testing vaccines and antivirals using human challenge
clinical trials. The company provides services to Big Pharma,
biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic, opened in February 2021,
and its 24-bedroom QMB clinic which also has a highly specialised
virology and immunology laboratory on-site. Open Orphan has a
leading portfolio of eight human challenge study models for
conditions such as RSV, flu, asthma and COPD. In addition, Open
Orphan is also developing the world's first COVID-19 human
challenge study model as part of the Human Challenge Programme and
has signed a reservation contract with the UK Government for the
first three COVID-19 vaccine challenge studies.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma and biotech companies. Following COVID-19 there is now a
renewed interest and investment in infectious diseases.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTEAKDPELDFEFA
(END) Dow Jones Newswires
March 09, 2021 02:00 ET (07:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024